| Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. | |
| | |
MedLine Citation:
|
PMID: 15967849 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Previous studies have reported that blood pressure response to antihypertensive medications is influenced by genetic variation in the renin-angiotensin-aldosterone system, but no clinical trails have tested whether the ACE insertion/deletion (I/D) polymorphism modifies the association between the type of medication and multiple cardiovascular and renal phenotypes. METHODS AND RESULTS: We used a double-blind, active-controlled randomized trial of antihypertensive treatment that included hypertensives > or =55 years of age with > or =1 risk factor for cardiovascular disease. ACE I/D genotypes were determined in 37 939 participants randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin treatments and followed up for 4 to 8 years. Primary outcomes included fatal coronary heart disease (CHD) and/or nonfatal myocardial infarction. Secondary outcomes included stroke, all-cause mortality, combined CHD, and combined cardiovascular disease. Fatal and nonfatal CHD occurred in 3096 individuals during follow-up. The hazard rates for fatal and nonfatal CHD and the secondary outcomes were similar across antihypertensive treatments. ACE I/D genotype group was not associated with fatal and nonfatal CHD (relative risk of DD versus ID and II, 0.99; 95% CI, 0.91 to 1.07) or any secondary outcome. The 6-year hazard rate for fatal and nonfatal CHD in the DD genotype group was not statistically different from the ID and II genotype group by type of treatment. No secondary outcome measure was statistically different across antihypertensive treatment and ACE I/D genotype strata. CONCLUSIONS: ACE I/D genotype group was not a predictor of CHD, nor did it modify the response to antihypertensive treatment. We conclude that the ACE I/D polymorphism is not a useful marker to predict antihypertensive treatment response. |
| | |
Authors:
|
Donna K Arnett; Barry R Davis; Charles E Ford; Eric Boerwinkle; Cathie Leiendecker-Foster; Michael B Miller; Henry Black; John H Eckfeldt |
Related Documents
:
|
9631869 - Indications for ace inhibitors in the early treatment of acute myocardial infarction: s... 12585949 - Effects of initiating carvedilol in patients with severe chronic heart failure: results... 12381079 - Long-term survival of non-elderly patients with severe heart failure treated with angio... 22503099 - Laser-assisted nasal decolonization of staphylococcus aureus, including methicillin-res... 3325229 - Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary h... 15642809 - Bronchial reactivity in healthy individuals undergoing long-term topical treatment with... 22994669 - Adverse effects of intralesional meglumine antimoniate and its influence on clinical la... 21963069 - A randomized comparison of ultrathin and standard colonoscope in cecal intubation rate ... 21533539 - Major functional deficits persist 2 years after acute achilles tendon rupture. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. Date: 2005-06-20 |
Journal Detail:
|
Title: Circulation Volume: 111 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2005 Jun |
Date Detail:
|
Created Date: 2005-06-28 Completed Date: 2006-02-03 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 3374-83 Citation Subset: AIM; IM |
Affiliation:
|
University of Minnesota, Division of Epidemiology, Minneapolis, USA. arnett@ms.soph.uab.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Amlodipine / administration & dosage, pharmacology Antihypertensive Agents / administration & dosage, pharmacology* Blood Pressure / drug effects*, genetics Cardiovascular Diseases / etiology* Chlorthalidone / administration & dosage, pharmacology Double-Blind Method Doxazosin / administration & dosage, pharmacology Female Follow-Up Studies Genotype Humans Lisinopril / administration & dosage, pharmacology Male Middle Aged Peptidyl-Dipeptidase A / genetics* Pharmacogenetics Polymorphism, Genetic* Predictive Value of Tests Proportional Hazards Models Risk Factors Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
5 R01 HL-63082/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 74191-85-8/Doxazosin; 77-36-1/Chlorthalidone; 83915-83-7/Lisinopril; 88150-42-9/Amlodipine; EC 3.4.15.1/Peptidyl-Dipeptidase A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Improved myocardial beta-adrenergic responsiveness and signaling with exercise training in hypertens...
Next Document: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events ...